| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,290,000 |
| Market
Cap: |
207.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.98 - $17.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Neuropace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Co.'s differentiated RNS System is the commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. Co.'s RNS System is also the only commercially available device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
390,291 |
| Total Buy Value |
$0 |
$0 |
$0 |
$585,047 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
597,632 |
684,372 |
692,686 |
692,686 |
| Total Sell Value |
$8,611,787 |
$9,592,721 |
$9,668,170 |
$9,668,170 |
| Total People Sold |
1 |
3 |
3 |
3 |
| Total Sell Transactions |
12 |
28 |
30 |
30 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Favet Michael |
Chief Executive Officer |
• • – |
2021-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
26,590 |
26,590 |
|
- |
|
| Morrell Martha |
Chief Medical officer |
• – – |
2021-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,181 |
9,699 |
|
- |
|
| Ridley Irina |
General Counsel and Secretary |
• – – |
2021-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,681 |
8,033 |
|
- |
|
| Fischer Frank M |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
472,366 |
565,657 |
|
- |
|
| Garfield Greg Shaw |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
5,614,384 |
5,614,384 |
|
- |
|
| Lacob Joseph |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
334,027 |
351,920 |
|
- |
|
| Favet Michael |
Chief Executive Officer |
• • – |
2021-04-26 |
4 |
A |
$0.03 |
$462 |
I/I |
15,385 |
22,947 |
|
- |
|
| Favet Michael |
Chief Executive Officer |
• • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
7,562 |
7,562 |
|
- |
|
| Norton Evan |
Director |
– • – |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
3,454,422 |
4,042,657 |
|
- |
|
| Kck Ltd. |
10% Owner |
– – • |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,595,493 |
5,621,111 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
3,777,281 |
4,012,281 |
|
- |
|
| Accelmed Partners Ii L.p. |
10% Owner |
– – • |
2021-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,454,422 |
4,042,657 |
|
- |
|
| Accelmed Partners Ii L.p. |
10% Owner |
– – • |
2021-04-21 |
4 |
B |
$17.00 |
$9,999,995 |
D/D |
588,235 |
588,235 |
2.45 |
- |
|
| Garfield Greg Shaw |
Director |
– • – |
2021-04-21 |
4 |
B |
$17.00 |
$224,995 |
D/D |
13,235 |
38,853 |
2.39 |
- |
|
| Ridley Irina |
General Counsel and Secretary |
• – – |
2021-04-21 |
4 |
B |
$17.00 |
$39,984 |
D/D |
2,352 |
2,352 |
2.74 |
- |
|
| Norton Evan |
Director |
– • – |
2021-04-21 |
4 |
B |
$17.00 |
$9,999,995 |
I/I |
588,235 |
588,235 |
2.1 |
- |
|
| Orbimed Capital Gp Vi Llc |
10% Owner |
– – • |
2021-04-21 |
4 |
B |
$17.00 |
$3,995,000 |
I/I |
235,000 |
235,000 |
1.5 |
- |
|
| Fischer Frank M |
Director |
– • – |
2021-04-21 |
4 |
B |
$17.00 |
$850,000 |
D/D |
50,000 |
93,291 |
2.39 |
- |
|
| Morrell Martha |
Chief Medical officerOfficer |
• – – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,518 |
|
- |
|
| Kck Ltd. |
10% Owner |
– – • |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,618 |
|
- |
|
| Kuhn Rebecca |
Chief Financial OfficerOfficer |
• – – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,226 |
|
- |
|
| Garfield Greg Shaw |
Director |
– • – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,618 |
|
- |
|
| Favet Michael |
Chief Executive OfficerOfficer |
• • – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,385 |
|
- |
|
| Ryan Renee |
Director |
– • – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,170 |
|
- |
|
| Fischer Frank M |
Director |
– • – |
2021-04-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
43,291 |
|
- |
|
77 Records found
|
|
Page 3 of 4 |
|
|
0.47 (5.2%) 
